Bio-Gene Technology Ltd. ( (AU:BGT) ) just unveiled an update.
Bio-Gene Technology Limited announced its participation in the NWR Virtual Healthcare Conference 2025, where CEO Tim Grogan will present the company’s advancements in bio-insecticides. This presentation highlights Bio-Gene’s commitment to addressing insecticide resistance and toxicity issues, potentially enhancing its market position and offering stakeholders innovative solutions for pest management.
More about Bio-Gene Technology Ltd.
Bio-Gene Technology Limited is an Australian company focused on developing novel bio-insecticides to tackle global challenges such as insecticide resistance and toxicity. Their products, based on naturally occurring compounds, aim to control pests effectively while minimizing impacts on human health and the environment. Bio-Gene’s solutions have applications in public health, crop protection, grain storage, and consumer use, meeting the demand for safe and effective pest management.
YTD Price Performance: -25.00%
Average Trading Volume: 1,033,533
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$6.04M
For a thorough assessment of BGT stock, go to TipRanks’ Stock Analysis page.